Study of GB261 for severe lupus
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new medicine, GB261, for people with active lupus who haven't responded well to other treatments. It aims to see if GB261 can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been diagnosed with lupus (SLE) using standard criteria.
- You must have active lupus that has not responded well to other treatments.
- You must test positive for at least 2 of 3 specific lupus antibodies.
- If you have lupus kidney disease (nephritis), you must have a recent kidney biopsy showing a certain type.
- You cannot have other serious health conditions or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This trial tests two biologic drugs (belimumab or telitacicept) compared to a standard treatment (mycophenolate mofetil) for people with active lupus nephritis. The goal is to see if biologics work better at controlling kidney inflammation over 6 months.
This trial tests a new drug called 626 for people with systemic lupus erythematosus (SLE). It aims to see if the drug is safe and effective at reducing disease activity.
This trial tests a new treatment called ACE1831 for people with moderate to severe lupus that has not improved with standard treatments like steroids or other medications. The goal is to see if it can help control lupus activity.
This trial tests a new drug, GB261, for people with systemic sclerosis (a condition that causes thickening and hardening of the skin and can affect internal organs). It aims to see if it can help when other treatments haven't worked well enough.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.